The Phase 1 portion of the study will determine the maximum tolerated dose of MB-102.~The Phase 2 portion of the trial will evaluate the efficacy of MB-102 in relapsed or refractory BPDCN.
A phase 1/2 study to assess the safety and efficacy of MB-102 in patients with relapsed or refractory BPDCN